RT Journal Article
SR Electronic
T1 Common variants in Alzheimer’s disease: Novel association of six genetic variants with AD and risk stratification by polygenic risk scores
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 19012021
DO 10.1101/19012021
A1 de Rojas, Itziar
A1 Moreno-Grau, Sonia
A1 Tesi, Niccolò
A1 Grenier-Boley, Benjamin
A1 Andrade, Victor
A1 Jansen, Iris
A1 Pedersen, Nancy L.
A1 Stringa, Najada
A1 Zettergren, Anna
A1 Hernández, Isabel
A1 Montrreal, Laura
A1 Antúnez, Carmen
A1 Antonell, Anna
A1 Tankard, Rick M.
A1 Bis, Joshua C.
A1 Sims, Rebecca
A1 Bellenguez, Céline
A1 Quintela, Inés
A1 González-Perez, Antonio
A1 Calero, Miguel
A1 Franco, Emilio
A1 Macías, Juan
A1 Blesa, Rafael
A1 Menéndez-González, Manuel
A1 Frank-García, Ana
A1 Luís Royo, Jose
A1 Moreno, Fermín
A1 Huerto, Raquel
A1 Baquero, Miquel
A1 Diez-Fairen, Mónica
A1 Lage, Carmen
A1 Garcia-Madrona, Sebastian
A1 García, Pablo
A1 Alarcón-Martín, Emilio
A1 Valero, Sergi
A1 Sotolongo-Grau, Oscar
A1 EADB, GR@ACE, DEGESCO, IGAP (ADGC, CHARGE, EADI, GERAD) and PGC-ALZ Consortia
A1 Garcia-Ribas, Guillermo
A1 Sánchez-Juan, Pascual
A1 Pastor, Pau
A1 Pérez-Tur, Jordi
A1 Piñol-Ripoll, Gerard
A1 de Munain, Adolfo Lopez
A1 García-Alberca, Jose María
A1 Bullido, María J.
A1 Álvarez, Victoria
A1 Lleó, Alberto
A1 Real, Luis M.
A1 Mir, Pablo
A1 Medina, Miguel
A1 Scheltens, Philip
A1 Holstege, Henne
A1 Marquié, Marta
A1 Sáez, María Eugenia
A1 Carracedo, Ángel
A1 Amouyel, Philippe
A1 Williams, Julie
A1 Seshadri, Sudha
A1 van Duijn, Cornelia M.
A1 Mather, Karen A.
A1 Sánchez-Valle, Raquel
A1 Serrano-Ríos, Manuel
A1 Orellana, Adelina
A1 Tárraga, Lluís
A1 Blennow, Kaj
A1 Huisman, Martijn
A1 Andreassen, Ole A.
A1 Posthuma, Danielle
A1 Clarimón, Jordi
A1 Boada, Mercè
A1 van der Flier, Wiesje M.
A1 Ramirez, Alfredo
A1 Lambert, Jean-Charles
A1 van der Lee, Sven J.
A1 Ruiz, Agustín
YR 2020
UL http://medrxiv.org/content/early/2020/01/17/19012021.abstract
AB BACKGROUND Disentangling the genetic constellation underlying Alzheimer’s disease (AD) is important. Doing so allows us to identify biological pathways underlying AD, point towards novel drug targets and use the variants for individualised risk predictions in disease modifying or prevention trials. In the present work we report on the largest genome-wide association study (GWAS) for AD risk to date and show the combined utility of proven AD loci for precision medicine using polygenic risk scores (PRS).METHODS Three sets of summary statistics were included in our meta-GWAS of AD: an Spanish case-control study (GR@ACE/DEGESCO study, n = 12,386), the case-control study of International Genomics of Alzheimer project (IGAP, n = 82,771) and the UK Biobank (UKB) AD-by-proxy case-control study (n=314,278). Using these resources, we performed a fixed-effects inverse-variance-weighted meta-analysis. Detected loci were confirmed in a replication study of 19,089 AD cases and 39,101 controls from 16 European-ancestry cohorts not previously used. We constructed a weighted PRS based on the 39 AD variants. PRS were generated by multiplying the genotype dosage of each risk allele for each variant by its respective weight, and then summing across all variants. We first validated it for AD in independent data (assessing effects of sub-threshold signal, diagnostic certainty, age at onset and sex) and tested its effect on risk (odds for disease) and age at onset in the GR@ACE/DEGESCO study.FINDINGS Using our meta-GWAS approach and follow-up analysis, we identified novel genome-wide significant associations of six genetic variants with AD risk (rs72835061-CHRNE, rs2154481-APP, rs876461-PRKD3/NDUFAF7, rs3935877-PLCG2 and two missense variants: rs34173062/rs34674752 in SHARPIN gene) and confirmed a stop codon mutation in the IL34 gene increasing the risk of AD (IL34-Tyr213Ter), and two other variants in PLCG2 and HS3ST1 regions. This brings the total number of genetic variants associated with AD to 39 (excluding APOE). The PRS based on these variants was associated with AD in an independent clinical AD-case control dataset (OR=1.30, per 1-SD increase in the PRS, 95%CI 1.18-1.44, p = 1.1×10−7), a similar effect to that in the GR@ACE/DEGESCO (OR=1.27, 95%CI 1.23-1.32, p = 7.4×10−39). We then explored the combined effects of these 39 variants in a PRS for AD risk and age-at-onset stratification in GR@ACE/DEGESCO. Excluding APOE, we observed a gradual risk increase over the 2% tiles; when comparing the extremes, those with the 2% highest risk had a 2.98-fold (95% CI 2.12–4.18, p = 3.2×10−10) increased risk compared to those with the 2% lowest risk (p = 5.9×10−10). Using the PRS we identified APOE ε33 carriers with a similar risk as APOE ε4 heterozygotes carriers, as well as APOE ε4 heterozygote carriers with a similar risk as APOE ε4 homozygote. Considering age at onset; there was a 9-year difference between median onset of AD the lowest risk group and the highest risk group (82 vs 73 years; p = 1.6×10−6); a 4-year median onset difference (81 vs 77 years; p = 6.9×10−5) within APOE ε4 heterozygotes and a 5.5-year median onset difference (78.5 vs 73 years; p = 4.6×10−5) within APOE ε4 carriers.INTERPRETATION We identified six novel genetic variants associated with AD-risk, among which one common APP variant. A PRS of all genetic loci reported to date could be a robust tool to predict the risk and age at onset of AD, beyond APOE alone. These properties make PRS instrumental in selecting individuals at risk in order to apply preventative strategies and might have potential use in diagnostic work-up.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe Genome Research @ Fundació ACE project (GR@ACE) is supported by Grifols SA, Fundación bancaria ‘La Caixa’, Fundació ACE, and CIBERNED. A.R. and M.B. receive support from the European Union/EFPIA Innovative Medicines Initiative Joint undertaking ADAPTED and MOPEAD projects (grant numbers 115975 and 115985, respectively). M.B. and A.R. are also supported by national grants PI13/02434, PI16/01861, PI17/01474 and PI19/01240. Acción Estratégica en Salud is integrated into the Spanish National R + D + I Plan and funded by ISCIII (Instituto de Salud Carlos III)–Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER–’Una manera de hacer Europ’). Amsterdam dementia Cohort (ADC): Research of the Alzheimer center Amsterdam is part of the neurodegeneration research program of Amsterdam Neuroscience. The Alzheimer Center Amsterdam is supported by Stichting Alzheimer Nederland and Stichting VUmc fonds. The clinical database structure was developed with funding from Stichting Dioraphte. Genotyping of the Dutch case-control samples was performed in the context of EADB (European Alzheimer DNA biobank) funded by the JPco-fuND FP-829-029 (ZonMW projectnumber 733051061). 100-Plus study: This work was supported by Stichting Alzheimer Nederland (WE09.2014-03), Stichting Diorapthe, horstingstuit foundation, Memorabel (ZonMW projectnumber 733050814) and Stichting VUmc Fonds. Genotyping of the 100-Plus Study was performed in the context of EADB (European Alzheimer DNA biobank) funded by the JPco-fuND FP-829-029 (ZonMW projectnumber 733051061). Longitudinal Aging Study Amsterdam (LASA) is largely supported by a grant from the Netherlands Ministry of Health, Welfare and Sports, Directorate of Long-Term Care.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNot Applicable